Patents Assigned to Siwa Corporation
-
Patent number: 11958900Abstract: A method of treating a neurodegenerative disorder or MD comprises administering to a subject a composition comprising an AGE antibody.Type: GrantFiled: April 14, 2017Date of Patent: April 16, 2024Assignee: SIWA CorporationInventor: Lewis S. Gruber
-
Patent number: 11872269Abstract: A method of treating sarcopenia comprises immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell. Immunizing a subject includes administering a vaccine that comprises an AGE antigen. Vaccines against AGE-modified proteins or peptides contain an AGE antigen, an adjuvant, optional preservatives and optional excipients.Type: GrantFiled: May 11, 2018Date of Patent: January 16, 2024Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 11873345Abstract: A method of treating sarcopenia comprises administering to a subject a composition comprising an anti-AGE antibody. The method may also be used for preventing or delaying the onset of cataracts, preventing or delaying the onset of loss of adipose tissue, increasing health span, and preventing or delaying the onset of lordokyphosis.Type: GrantFiled: June 13, 2019Date of Patent: January 16, 2024Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 11833202Abstract: A method of treating cancer, killing metastatic cancer cells, killing potentially-malignant neoplasm cells and/or preventing cancer metastasis comprises administering to a subject a composition comprising an anti-AGE antibody. A method of diagnosing metastatic cancer comprises detecting an immune complex comprising an anti-AGE antibody bound to a cell expressing an AGE modification.Type: GrantFiled: February 16, 2017Date of Patent: December 5, 2023Assignee: SIWA CorporationInventor: Lewis S. Gruber
-
Patent number: 11542324Abstract: A humanized monoclonal antibody that binds to an advanced glycation end-product-modified protein or peptide on a cell comprises a heavy chain and a light chain. The antibody binds a carboxymethyllysine-modified protein or peptide. A composition comprises a humanized monoclonal antibody that binds to an advanced glycation end-product-modified protein or peptide on a cell and a pharmaceutically acceptable carrier.Type: GrantFiled: November 5, 2020Date of Patent: January 3, 2023Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 11518801Abstract: A method of treating or preventing the onset of diabetes or diabetic complications comprises administering to a subject a composition comprising an anti-AGE antibody. A composition for treating or preventing the onset of diabetes or diabetic complications comprises a first anti-AGE antibody, a second anti-AGE antibody and a pharmaceutically acceptable carrier. The first anti-AGE antibody is different from the second anti-AGE antibody. A method of treating or preventing the onset of diabetes or diabetic complications comprises immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell.Type: GrantFiled: December 20, 2018Date of Patent: December 6, 2022Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 11261241Abstract: Apparatuses, compositions and methods for removing cells which interfere with regenerative processes. The apparatuses, compositions and methods selectively kill partially functional and/or non-functional cells versus functional cells while protecting functional proliferative cells to the extent that, upon removal of the killed cells by disintegration or scavenging, functional cells replace the partially- or non-functional cells.Type: GrantFiled: September 29, 2017Date of Patent: March 1, 2022Assignee: SIWA CorporationInventor: Lewis S. Gruber
-
Patent number: 11213585Abstract: Various diseases and disorders associated with cellular senescence may be treated by immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell Immunizing a subject includes administering a vaccine that comprises an AGE antigen. Vaccines against AGE-modified proteins or peptides contain an AGE antigen, an adjuvant, optional preservatives and optional excipients.Type: GrantFiled: June 23, 2016Date of Patent: January 4, 2022Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 10995151Abstract: A method of treating disease-related cachexia comprises administering to a subject a composition comprising an anti-AGE antibody. A composition for treating disease-related cachexia comprises a first anti-AGE antibody, a second anti-AGE antibody and a pharmaceutically acceptable carrier. The first anti-AGE antibody is different from the second anti-AGE antibody. A method of treating or preventing the onset of disease-related cachexia comprises immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell.Type: GrantFiled: January 5, 2018Date of Patent: May 4, 2021Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 10960234Abstract: A method of treating a condition associate with accumulation of an agent in cells in a patient includes exposing the cells to ultrasound, to selectively kill or induce apoptosis in the cells. The cells include the accumulated agent.Type: GrantFiled: October 22, 2015Date of Patent: March 30, 2021Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 10961321Abstract: A method of treating pain associated with inflammation comprises administering to a subject a composition comprising an anti-AGE antibody. A composition for treating pain associated with inflammation comprises a first anti-AGE antibody, a second anti-AGE antibody and a pharmaceutically acceptable carrier. The first anti-AGE antibody is different from the second anti-AGE antibody. A method of treating or preventing the onset of pain associated with inflammation comprises immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell.Type: GrantFiled: January 5, 2018Date of Patent: March 30, 2021Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 10925937Abstract: Various juvenile disorders associated with inflammation may be treated or prevented by immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell. Immunizing a subject includes administering a vaccine that comprises an AGE antigen. Vaccines against AGE-modified proteins or peptides contain an AGE antigen, an adjuvant, optional preservatives and optional excipients.Type: GrantFiled: January 5, 2018Date of Patent: February 23, 2021Assignee: Siwa CorporationInventors: Lewis S. Gruber, Misty S. Gruber
-
Patent number: 10919957Abstract: A humanized monoclonal antibody that binds to an advanced glycation end-product-modified protein or peptide on a cell comprises a heavy chain and a light chain. The antibody binds a carboxymethyllysine-modified protein or peptide. A composition comprises a humanized monoclonal antibody that binds to an advanced glycation end-product-modified protein or peptide on a cell and a pharmaceutically acceptable carrier.Type: GrantFiled: April 13, 2018Date of Patent: February 16, 2021Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 10889634Abstract: An anti-AGE antibody comprises a protein or peptide that comprises at least one amino acid sequence having at least 90% sequence identity, preferably at least 95% sequence identity, more preferably at least 98% sequence identity, with specific amino acid sequences. The anti-AGE antibody binds to a protein or peptide that exhibits a carboxymethyllysine modification. The anti-AGE antibody may be used for killing senescent cells, killing partially-functional or non-functional cells, treating sarcopenia, promoting tissue or organ regeneration, promoting regenerative processes or overcoming aging effects, treating atherosclerosis, preventing or delaying the onset of cataracts, preventing or delaying the onset of loss of adipose tissue, increasing health span, preventing or delaying the onset of lordokyphosis, treating inflammation or autoimmune disorders, treating neurodegenerative disorders or treating cancer.Type: GrantFiled: May 27, 2016Date of Patent: January 12, 2021Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 10858449Abstract: A method of treating osteoarthritis comprises administering to a subject a composition comprising an anti-AGE antibody. A composition for treating osteoarthritis comprises a first anti-AGE antibody, a second anti-AGE antibody and a pharmaceutically acceptable carrier. The first anti-AGE antibody is different from the second anti-AGE antibody. The anti-AGE antibody may be administered intra-articularly into an affected joint. A method of treating or preventing the onset of osteoarthritis comprises immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell.Type: GrantFiled: January 5, 2018Date of Patent: December 8, 2020Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 10584180Abstract: A composition for treating inflammation or auto-immune disorders comprises (i) an antibody that binds to an AGE-modified protein on a cell, and (ii) an anti-inflammation antibody. Furthermore, the antibody that binds to an AGE-modified protein on a cell is also effective to treat inflammation or auto-immune disorders alone.Type: GrantFiled: September 15, 2015Date of Patent: March 10, 2020Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 10358502Abstract: A method of treating sarcopenia comprises administering to a subject a composition comprising an anti-AGE antibody. The method may also be used for preventing or delaying the onset of cataracts, preventing or delaying the onset of loss of adipose tissue, increasing health span, and preventing or delaying the onset of lordokyphosis.Type: GrantFiled: December 18, 2015Date of Patent: July 23, 2019Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 10226531Abstract: A method of treating atherosclerosis comprises removing AGE-modified cells from a patient. The AGE-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. A variety of techniques, such as ultrasound and binding with an anti-AGE antibody, may be used to identify and remove the AGE-modified cells.Type: GrantFiled: April 17, 2017Date of Patent: March 12, 2019Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 9993535Abstract: A method of treating sarcopenia comprises immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell. Immunizing a subject includes administering a vaccine that comprises an AGE antigen. Vaccines against AGE-modified proteins or peptides contain an AGE antigen, an adjuvant, optional preservatives and optional excipients.Type: GrantFiled: December 18, 2015Date of Patent: June 12, 2018Assignee: Siwa CorporationInventor: Lewis S. Gruber
-
Patent number: 9649376Abstract: A method of treating atherosclerosis comprises removing AGE-modified cells from a patient. The AGE-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. A variety of techniques, such as ultrasound and binding with an anti-AGE antibody, may be used to identify and remove the AGE-modified cells.Type: GrantFiled: September 27, 2011Date of Patent: May 16, 2017Assignee: Siwa CorporationInventor: Lewis Gruber